J Neurosurg Spine. 2017 Apr;26(4):494-500. doi: 10.3171/2016.9.SPINE16778. Epub 2017 Jan 13.
OBJECTIVE The objective of this study was to review clinical outcomes following resection of giant spinal schwannomas. METHODS The authors conducted a retrospective review of a case series of patients with giant spinal schwannomas at a tertiary cancer hospital. RESULTS Thirty-two patients with giant spinal schwannomas underwent surgery between September 1998 and May 2013. Tumor size ranged from 2.5 cm to 14.6 cm with a median size of 5.8 cm. There were 9 females (28.1%) and 23 males (71.9%), and the median age was 47 years (range 23-83 years). The median follow-up duration was 36.0 months (range 12.2-132.4 months). Three patients (9.4%) experienced recurrence and required further treatment. All recurrences developed following subtotal resection (STR) of cellular or melanotic schwannoma. There were 3 melanotic (9.4%) and 6 cellular (18.8%) schwannomas included in this study. Among these histological variants, a 33.3% recurrence rate was noted. In 1 case of melanotic schwannoma, malignant transformation occurred. No recurrence occurred following gross-total resection (GTR) or when a fibrous capsule remained due to its adherence to functional nerve roots. CONCLUSIONS Resection is the treatment of choice for symptomatic or growing giant schwannomas, frequently requiring anterior or combined approaches, with the goals of symptom relief and prevention of recurrence. In this series, tumors that underwent GTR, or where only capsule remained, did not recur. Only melanotic and cellular schwannomas that underwent STR recurred.
目的 本研究的目的是回顾巨大脊髓神经鞘瘤切除术后的临床结果。方法 作者对一家三级癌症医院的一系列巨大脊髓神经鞘瘤患者病例进行了回顾性研究。结果 1998年9月至2013年5月期间,32例巨大脊髓神经鞘瘤患者接受了手术。肿瘤大小范围为2.5 cm至14.6 cm,中位大小为5.8 cm。女性9例(28.1%),男性23例(71.9%),中位年龄为47岁(范围23 - 83岁)。中位随访时间为36.0个月(范围12.2 - 132.4个月)。3例患者(9.4%)出现复发,需要进一步治疗。所有复发均发生在细胞型或黑色素型神经鞘瘤次全切除(STR)之后。本研究包括3例黑色素型(9.4%)和6例细胞型(18.8%)神经鞘瘤。在这些组织学变体中,复发率为33.3%。在1例黑色素型神经鞘瘤中发生了恶性转化。全切除(GTR)后或因与功能性神经根粘连而保留纤维包膜时未发生复发。结论 手术切除是有症状或生长性巨大神经鞘瘤的首选治疗方法,通常需要前路或联合入路,目标是缓解症状和预防复发。在本系列中,接受GTR或仅保留包膜的肿瘤未复发。仅接受STR的黑色素型和细胞型神经鞘瘤复发。